New Oral IL-23 Receptor Antagonist Peptide Effective in PASI Reduction for Psoriasis
These new data highlight the efficacy of JNJ-77242113 as a potential oral therapy option for moderate-to-severe psoriasis patients.
Source: hcplive.com
Signs Diary News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Signs Diary. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Signs Diary Today - Breaking & Trending Today
New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113
JNJ-2113 achieved all primary and secondary endpoints in the Phase 2b clinical trial FRONTIER 1, including PASI 100 and IGA 0 responses of 40.5 percent and 45.2 percent, respectively.NEWARK, CA / ACCESSWIRE / February 7, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Compan...
Source: pharmiweb.com
Guselkumab Shows Significant Scalp Psoriasis Clearance in People of Color
Guselkumab significantly and rapidly improved severe scalp psoriasis, itch, and patient-reported HRQOL outcomes in patients of color.
Source: clinicaladvisor.com
New England Journal of Medicine Publishes Efficacy and Safety Data ...
New England Journal of Medicine Publishes Efficacy and Safety Data ...
Source: pr-inside.com
Investigational targeted oral peptide JNJ-2113 demonstrated positive results in moderate-to-severe plaque psoriasis in Phase 2b study published in New England Journal of Medicine
/PRNewswire/ -- Johnson & Johnson today announced publication in the New England Journal of Medicine (NEJM) of the Phase 2b FRONTIER 1 trial results for...
Source: prnewswire.com